Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amoxicillin + paracetamol is a fixed-dose or co-administered combination of a broad-spectrum penicillin antibiotic and a non-opioid analgesic/antipyretic. Amoxicillin, a beta-lactam antibiotic, acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), which leads to bacterial lysis and death. Paracetamol (acetaminophen) provides analgesic and antipyretic effects, primarily through the inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of endogenous cannabinoid and serotonergic pathways. This combination is typically indicated for the management of bacterial infections accompanied by pain or fever, such as dental abscesses, otitis media, or respiratory tract infections, where symptomatic relief is required alongside antimicrobial therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + paracetamol.